Frazier Life Sciences Management L.P. Raises Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

Frazier Life Sciences Management L.P. increased its position in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,175,665 shares of the biopharmaceutical company's stock after acquiring an additional 164,938 shares during the quarter. Frazier Life Sciences Management L.P. owned approximately 5.06% of MacroGenics worth $10,321,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Wasatch Advisors LP boosted its position in shares of MacroGenics by 37.6% during the 4th quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company's stock valued at $11,338,000 after acquiring an additional 952,691 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of MacroGenics by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 1,433,217 shares of the biopharmaceutical company's stock valued at $4,659,000 after acquiring an additional 26,341 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of MacroGenics by 7.1% during the 4th quarter. Two Sigma Advisers LP now owns 1,118,600 shares of the biopharmaceutical company's stock valued at $3,635,000 after acquiring an additional 74,596 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of MacroGenics during the 4th quarter valued at about $2,787,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of MacroGenics by 12.5% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 744,902 shares of the biopharmaceutical company's stock valued at $2,421,000 after acquiring an additional 82,988 shares during the last quarter. Institutional investors and hedge funds own 96.89% of the company's stock.

MacroGenics Stock Down 4.4%

NASDAQ:MGNX traded down $0.07 on Friday, reaching $1.51. 273,887 shares of the company's stock were exchanged, compared to its average volume of 802,840. The firm has a market capitalization of $95.27 million, a price-to-earnings ratio of -0.96 and a beta of 2.20. The business has a fifty day moving average of $1.49 and a 200-day moving average of $2.54. MacroGenics, Inc. has a 52-week low of $0.99 and a 52-week high of $5.77.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). The business had revenue of $13.19 million for the quarter, compared to analysts' expectations of $9.59 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. As a group, equities analysts anticipate that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Analyst Ratings Changes

MGNX has been the topic of several research analyst reports. Barclays restated an "overweight" rating and issued a $3.00 price objective (down from $8.00) on shares of MacroGenics in a report on Wednesday, May 14th. Wall Street Zen lowered shares of MacroGenics from a "hold" rating to a "sell" rating in a report on Thursday. Stifel Nicolaus reduced their price objective on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating on the stock in a report on Wednesday, May 14th. B. Riley reduced their price objective on shares of MacroGenics from $5.00 to $3.00 and set a "neutral" rating on the stock in a report on Tuesday. Finally, HC Wainwright reduced their price objective on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, March 25th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $6.13.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.